Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SPP1
REST API REST API
Homo sapiens
SPP1 is differentially expressed in 263 experiments: 189 organism parts: kidney, ovary, ... (187 more);, 189 disease states: normal, glioblastoma, ... (187 more);, 82 cell types 407 cell lines 33 compound treatments and 70 other conditions.
Synonyms ETA-1, BNSP, OPN, BSPI
Orthologs Q58DM6_BOVIN (Bos taurus)   SPP1 (Gallus gallus)   Spp1 (Mus musculus)   LOC100359743 (Rattus norvegicus)   Q3HTT3_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytoplasm, extracellular space, extracellular region, cytokine activity, cell differentiation, cell adhesion, cell projection, perinuclear region of cytoplasm, apical part of cell, positive regulation of cell-substrate adhesion, response to vitamin D, decidualization, positive regulation of bone resorption, negative regulation of collateral sprouting of intact axon in response to injury, membrane-bounded vesicle, extracellular matrix binding, osteoblast differentiation, ossification, inflammatory response, response to organic substance, response to steroid hormone stimulus, embryo implantation, biomineral tissue development
InterPro Term Osteopontin
UniProt Accession Q567T5, Q3LGB0, Q4W597, D6R9C5, B2RDA1, P10451, C9JXD2, F2YBS4
Search EB-eye ENSG00000118785
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-2549, E-GEOD-7540, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, ... (36 experiments)

Factor Value U/D Experiments
primary culture
2
E-GEOD-2450, E-GEOD-1657
A549
2
E-GEOD-3202, E-GEOD-6013
BT474
2
E-MTAB-62, E-MTAB-37
HL-60
2
E-GEOD-5258, E-GEOD-24147
U251
2
E-GEOD-20089, E-MTAB-62
SW480
1
2
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
401 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-360, E-GEOD-20677, E-GEOD-21750, ... (39 experiments)

Factor Value U/D Experiments
monocyte
4
E-GEOD-5099, E-GEOD-995, E-MEXP-583, E-MEXP-2019
dendritic cell
3
E-GEOD-3982, E-MEXP-2019, E-GEOD-360
macrophage
3
E-GEOD-3982, E-GEOD-5099, E-GEOD-360
human embryonic stem cell
2
E-GEOD-18147, E-GEOD-18265
endothelial cell
2
E-GEOD-3920, E-GEOD-19240
CD34+CD38-/lowCD19+ cell
1
E-MEXP-1403
76 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (62 experiments)

Factor Value U/D Experiments
glioblastoma
1
5
E-GEOD-6014, E-GEOD-4290, E-MTAB-37, E-MTAB-62, E-GEOD-4412, ... (6 experiments)
lung adenocarcinoma
4
E-GEOD-2514, E-MEXP-231, E-MTAB-62, E-MTAB-37
Duchenne muscular dystrophy
3
E-GEOD-1007, E-GEOD-1004, E-GEOD-3307
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-MTAB-57
prostate carcinoma
3
E-MTAB-62, E-GEOD-96, E-GEOD-7307
leiomyosarcoma
2
E-MTAB-62, E-MEXP-1922
183 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-TABM-782, E-GEOD-697, E-GEOD-3720, ... (21 experiments)

Factor Value U/D Experiments
granulocyte-macrophage colony-stimulating factor + interleukin 4
1
E-MEXP-2000
U0126
1
E-GEOD-697
phoshate buffered saline
1
E-GEOD-3720
interferon-gamma + lipopolysaccharide
1
E-GEOD-7307
N-nitrosodimethylamine
1
E-GEOD-6907
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
27 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MTAB-62

Dfs follow up
studied in E-GEOD-22541

Disease free interval dfi in months
studied in E-GEOD-22541

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-GEOD-18005, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-MEXP-1446, E-GEOD-22278, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-GEOD-1926, E-GEOD-10433, E-GEOD-3606, E-TABM-118, ... (31 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-MEXP-1403

Population
studied in E-GEOD-4342

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-15811

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-7540, E-GEOD-7307

Stimulation
studied in E-GEOD-23984, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

tissue (organ)
studied in E-GEOD-22601

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-21909, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561

Processing time: 0.402 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM